Look at what the market says; the big boys look also to acquisition in addition to product development, if UEEC patents are solid; and we could get 2 or more interested parties bidding; a nice price could well be in the offering. The existing lower level approvals should be marketable at least $1 per share if FDA rejects the current PMA. I am still a buyer; albeit just 1 to 2 K per week; but I gamble.